Literature DB >> 21623910

Is arteriolar vacuolization a predictor of calcineurin inhibitor nephrotoxicity?

Keiji Horike1, Asami Takeda, Yutaka Yamaguchi, Yoshiaki Ogiyama, Yukako Yamauchi, Minako Murata, Takehiko Kawaguchi, Taisei Suzuki, Yasuhiro Otsuka, Daijyo Inaguma, Norihiko Goto, Yoshihiko Watarai, Kazuharu Uchida, Kunio Morozumi.   

Abstract

Calcineurin inhibitors (CNI) have been commonly used as pivotal immunosuppressive agents to renal transplant recipients and have contributed significantly to improving short-term allograft survival. However, long-term administration of CNI may cause an adverse effect on kidney function, known as chronic nephrotoxicity. Chronic CNI nephrotoxicity (CNI-NT) shows characteristic histopathological findings that involve arteriolar hyalinosis. Recently, the term alternative arteriolar hyalinosis (aah) is used to discriminate CNI-specific arteriolar hyaline deposition from non-specific arteriolar hyalinosis. We studied whether arteriolar vacuolization represents an early lesion of aah as a predictor of CNI-NT. We retrospectively studied the 79 patients under treatment with a CNI immunosuppressant, who underwent living-related renal transplantation (RTx) from January 2007 to March 2009. We examined serial protocol graft biopsies at one h, one, six, and 12 months after RTx. We classified histological findings into two groups on the basis of aah lesion (with or without aah) in serial biopsies for 12 months. Arteriolar vacuolization was more frequently observed in the aah group than in the non-aah group with a significant difference. Arteriolar vacuolization was found even in the one-h biopsy specimens, indicating a non-specific histopathological finding. But in the aah group, arteriolar vacuolization tended to be more frequently observed later on. Aah can be a predictor of CNI-NT.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623910     DOI: 10.1111/j.1399-0012.2011.01474.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

1.  Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.

Authors:  J Furuzawa-Carballeda; G Lima; J Alberú; D Palafox; N Uribe-Uribe; L E Morales-Buenrostro; R Reyes Acevedo; G Mondragón; A Chevaile; L Llorente
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

2.  Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years.

Authors:  J Furuzawa-Carballeda; N O Uribe-Uribe; J M Arreola-Guerra; R Reyes-Acevedo; M Vilatobá; A López-Toledo; G Mondragón-Salgado; R Chávez-Fernández; F López-Verdugo; G Mondragón-Ramírez; J Alberú
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

3.  The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome.

Authors:  Hiroki Mizuno; Naoki Sawa; Shun Watanabe; Daisuke Ikuma; Akinari Sekine; Masahiro Kawada; Masayuki Yamanouchi; Eiko Hasegawa; Tatsuya Suwabe; Junichi Hoshino; Kenmei Takaichi; Keiichi Kinowaki; Takeshi Fujii; Kenichi Ohashi; Michio Nagata; Yutaka Yamaguchi; Yoshifumi Ubara
Journal:  Kidney Int Rep       Date:  2020-05-19

4.  Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome.

Authors:  A Sinha; A Sharma; A Mehta; R Gupta; A Gulati; P Hari; A K Dinda; A Bagga
Journal:  Indian J Nephrol       Date:  2013-01

Review 5.  Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation.

Authors:  Rita Leal; Demetra Tsapepas; Russell J Crew; Geoffrey K Dube; Lloyd Ratner; Ibrahim Batal
Journal:  Kidney Int Rep       Date:  2017-10-27

6.  Renal Damage in Recurrent Atypical Hemolytic Uremic Syndrome Associated with C3 p.Ile1157Thr Gene Mutation.

Authors:  Masahiro Okabe; Arisa Kobayashi; Hirokazu Marumoto; Kentaro Koike; Izumi Yamamoto; Tetsuya Kawamura; Nobuo Tsuboi; Takashi Yokoo
Journal:  Intern Med       Date:  2020-10-21       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.